Exact Sciences Corporatio... (EXAS)
NASDAQ: EXAS
· Real-Time Price · USD
46.88
1.24 (2.72%)
At close: May 01, 2025, 11:13 AM
2.72% (1D)
| Bid | 46.85 |
| Market Cap | 8.71B |
| Revenue (ttm) | 2.76B |
| Net Income (ttm) | -1.03B |
| EPS (ttm) | -5.59 |
| PE Ratio (ttm) | -8.39 |
| Forward PE | 74.82 |
| Analyst | Buy |
| Ask | 46.93 |
| Volume | 968,341 |
| Avg. Volume (20D) | 2,342,475 |
| Open | 45.64 |
| Previous Close | 45.64 |
| Day's Range | 45.16 - 47.07 |
| 52-Week Range | 39.97 - 72.83 |
| Beta | 1.14 |
About EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid th...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Feb 1, 2001
Employees 6,900
Stock Exchange NASDAQ
Ticker Symbol EXAS
Website https://www.exactsciences.com
Analyst Forecast
According to 21 analyst ratings, the average rating for EXAS stock is "Buy." The 12-month stock price forecast is $67, which is an increase of 42.90% from the latest price.
Stock ForecastsNext Earnings Release
Exact Sciences Corporation is scheduled to release its earnings on May 1, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-1.92%
Exact Sciences shares are trading lower after Barc...
Unlock content with
Pro Subscription
5 months ago
+9%
Exact Sciences shares are trading higher. The company announced it will present 10 abstracts at SABCS.
